

treatments/day being required as long as contractile dysfunction continues. Thus, an injectable solution for intracoronary administration of an ACE inhibitor may be formulated with captopril or zofenopril or 1-(3-mercapto-2-D-methylpropanoyl)-L-proline 500 mg, Me paraben 5 mg, Pr paraben 1 mg NaCl 25 g, H2O for injection 5 L. A captopril formulation suitable for oral administration may contain captopril 100 g, corn starch 50 g, gelatin 7.5 g, Avicel 25 g, and Mg stearate 2.5 g.

=> d his

(FILE 'HOME' ENTERED AT 15:41:08 ON 15 FEB 2007)

FILE 'CAPLUS' ENTERED AT 15:41:21 ON 15 FEB 2007

| | |
|----|---------------------------------------|
| L1 | 432 S 105857-23-6/RN |
| L2 | 129 S TENECTEPLASE |
| L3 | 513 S L1 OR L2 |
| L4 | 513 DUP REM L3 (0 DUPLICATES REMOVED) |
| L5 | 513 S L4 |
| L6 | 199 S L4 AND PY<=2001 |
| L7 | 18197 S CATHETER |
| L8 | 7 S L6 AND L7 |

=>